Short course of R‐HyperCVAD/MTX/ARA‐C followed by ASCT as first‐line therapy in mantle cell lymphoma patients prolongs progression‐free survival to more than 9 years. (June 2017) - Andrade Campos, M.; Mercadal, S.; Domingo Domenech, E.; Paredes, V.; Aguilera, C.; Oliveira, A.; de la Banda, E.; Climent, F.; Parody, R.; Fernandez de Sevilla, A.; Sureda, A.; Gonzalez Barca, E.